Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.
about
Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activityClass I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes.Small-molecular modulators of cancer-associated epigenetic mechanisms.The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death.Histone deacetylase inhibitors: emerging mechanisms of resistance.Targeting Histone Deacetylases in Diseases: Where Are We?Current evidence for histone deacetylase inhibitors in pancreatic cancer.Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism.HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat.Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma.A decade of the human genome sequence--how does the medicinal chemist benefit?Targeting class I histone deacetylases in cancer therapy.HDAC inhibitor-based therapies: can we interpret the code?Reactivation of latent HIV by histone deacetylase inhibitors.Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer.Targeting cardiac fibroblasts to treat fibrosis of the heart: focus on HDACs.Progress and challenges in the use of latent HIV-1 reactivating agentsHistone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.The Effect of MGCD0103 on CYP450 Isoforms Activity of Rats by Cocktail Method.Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates.Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53.Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
P2860
Q33649465-25FE4072-4E94-4168-B02B-4683C1E8ECD2Q33998649-45F9D863-2D2B-4A4A-A550-8D146C32C34AQ34628002-5C848404-6E4F-4243-AD18-85D5BDA8EB81Q34662212-CE02E021-8F24-4671-95E7-34C06C413A49Q35592607-18F60212-2E0A-4974-B4CC-3A19E89951EAQ35821728-E385FA1C-D8E7-4182-BA50-7C986398FF19Q36616790-8417C30B-04E4-4BF6-9D9B-2A464E2F55C2Q36654454-2EAFB4A5-9879-450F-A6C9-4C88A6F489BEQ36929766-695687E2-4F77-4E13-B5C3-7328A59DB3BCQ37002069-AB320F4C-DE09-4443-99FF-9BAA50F00371Q37690128-9DEA13DE-D569-4874-B128-7D99092E837FQ37968558-EA456633-CE32-42D1-85E6-F60B4B2AE959Q38051736-E9D6E647-DE97-4302-BC16-E1E3869C2295Q38058971-5BCCDCBE-DE06-418A-BDF0-9A7062270EE0Q38091753-EE7C4FA0-35AF-4ADE-93FB-228E871661BFQ38155850-655EDC93-9E5C-4041-AC7A-E048E76A2EB6Q38196176-5999E8E3-ABBE-46EE-A1AB-EDD1EBC02E37Q38509230-CED50BDF-FF02-4B5D-A0BF-965D7BD637FAQ38595978-CF80210E-5CB7-44B4-8937-F1A4F67C98F8Q41556725-8280DF3A-8854-4B3B-81F4-E0808F50E33AQ41652576-DB63D3FB-3BBC-475C-8970-B694C32681BEQ43034405-6B83F309-515D-4E8A-88E7-CBBB7B32E5D4Q47130359-94FC8205-C5F2-4524-A560-23A26EF695F7Q47136872-3FC964E3-4CD6-419E-80E6-923447C0ACBEQ49853764-DB80D504-83AF-4881-85E0-8E607DF2C2A6Q51054177-78914F54-7B9A-4469-99A2-AD458EFEAF71
P2860
Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.
@en
Mocetinostat
@nl
type
label
Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.
@en
Mocetinostat
@nl
prefLabel
Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.
@en
Mocetinostat
@nl
P2860
P1476
Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.
@en
P2093
Anas Younes
Yanis Boumber
P2860
P304
P356
10.1517/13543784.2011.577737
P407
P577
2011-05-10T00:00:00Z